Pfizer Inc. — 2013 Form 10-K Summary
Business context and period. Pfizer is a global biopharmaceutical company. This annual report covers the fiscal year ended December 31, 2013; it is not a standalone fourth-quarter report. The supplied filing text refers key financial statements and MD&A information to the separate 2013 Financial Report, which is not included here.
Key financial and operating metrics
| Metric | 2013 disclosure in supplied text |
|---|---|
| Biopharmaceutical revenue | $47.9 billion, down 7% from 2012; operational revenue declined 4%, with foreign exchange reducing revenue by 3%. This business represented about 93% of total revenue. |
| Consumer Healthcare revenue | $3.3 billion, up 4% from 2012; operational growth of 5% was partly offset by a 1% unfavorable foreign-exchange impact. |
| Revenue outside the U.S. | $31.3 billion, or 61% of total revenue. International biopharmaceutical revenue declined 7% year over year. |
| Research and development | $6.7 billion in 2013, versus $7.5 billion in 2012 and $8.7 billion in 2011. |
| Animal Health disposition | Completed June 24, 2013. Pfizer received cash and debt relief totaling approximately $6.1 billion and Pfizer common shares valued at approximately $11.4 billion. |
| Share repurchases | 152.1 million shares purchased under publicly announced plans in Q4 2013, at an average price of $30.55 per share. Approximately $5.5 billion remained authorized at year-end. |
The supplied text does not provide clear consolidated revenue, net income, earnings per share, cash flow, margins, debt, cash balances, or detailed liquidity figures. It states management believed cash flows, financial assets, capital-market access, and credit facilities would support liquidity needs for the foreseeable future, but does not provide the underlying amounts here.
Material changes versus the prior comparable period
- Biopharmaceutical revenue fell 7% year over year, reflecting both operational decline and unfavorable currency movements.
- Consumer Healthcare revenue rose 4% year over year.
- R&D spending declined by $0.8 billion from 2012 to 2013.
- Pfizer completed the Animal Health disposition in June 2013; the Nutrition business had been sold in November 2012.
- Beginning in 2014, Pfizer reorganized commercial operations into three global businesses: Global Innovative Pharmaceutical; Global Vaccines, Oncology and Consumer Healthcare; and Global Established Pharmaceutical. The filing says 2013 results remain presented under the prior structure.
Outlook, commentary, risks, and unusual items
- The filing refers to 2014 financial guidance in the incorporated 2013 Financial Report, but the guidance values are not included in the supplied text.
- Management describes ongoing R&D and organizational transformation, with 279 R&D projects at year-end 2013, including 20 Phase 3 programs. Drug-development outcomes and commercial success remain uncertain.
- Key risks include generic competition and patent expirations, pricing and reimbursement pressure, dependence on major products, foreign-exchange exposure, regulatory and clinical-development uncertainty, litigation, and potential supply or manufacturing disruptions. Ten biopharmaceutical products each generated more than $1 billion in direct sales and together represented 51% of biopharmaceutical revenue.
- Pfizer reported that a third-party logistics company arranged certain authorized shipments to Iran on aircraft operated by designated carriers Iran Air or Aban Air. Pfizer reported no direct agreements or payments to those carriers, voluntarily disclosed the matter to the U.S. government, and said it was adding controls.
- Pfizer reported effective disclosure controls and no material fourth-quarter change in internal control over financial reporting. It also disclosed continuing systems and transaction-processing initiatives.
Important facts for investors to verify
- Review the incorporated 2013 Financial Report for consolidated revenue, earnings, cash flows, balance-sheet liquidity, debt, margins, segment results, contingencies, and the complete 2014 guidance.
- Assess the sustainability of biopharmaceutical revenue and the effect of upcoming patent expirations, generic competition, and collaboration changes.
- Review the financial and accounting effects of the Animal Health disposition, including treatment of the cash, debt relief, and shares received.
- Check the status and potential financial impact of significant litigation, regulatory matters, and the Iran shipment disclosure.
- Evaluate whether the 2014 commercial reorganization and ongoing cost and R&D initiatives deliver the expected results.